Skip to main content

Deep Track Capital, LP

13F filer · CIK 0001856083
Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$6.87BU.S. long equity reported on 13F
Positions6618 new · 14 closed
Net flow last quarter+$655MBuys minus sells
Top 10 positions weight39.6%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202666 positions
GHGuardant Health, Inc.$509M7.41%2.54%+1.7%Q2 2023
IMVTImmunovant, Inc.$360M5.24%4.53%-19.0%Q4 2021
GPCRStructure Therapeutics Inc.$254M3.70%2.22%+10.8%Q1 2023
PCVXVaxcyte, Inc.$250M3.64%2.97%Not reportedQ1 2025
ALNYAlnylam Pharmaceuticals, Inc.$248M3.61%0.62%Not reportedQ1 2022
MANEVeradermics, Inc$246M3.58%4.79%+300.0%Q1 2026
TARSTarsus Pharmaceuticals, Inc.$231M3.36%8.47%+1.9%Q1 2025
NUVLNuvalent, Inc.$220M3.21%56.99%+29.6%Q4 2023
ALKSAlkermes plc.$210M3.05%2.39%+11.4%Q1 2023
OCULOcular Therapeutix, Inc$193M2.81%8.97%Not reportedQ4 2023
BMRNBiomarin Pharmaceutical Inc$189M2.75%1.71%+187.6%Q2 2022
NRIXNurix Therapeutics, Inc.$188M2.73%7.45%+21.9%Q2 2022
ORKAOruka Therapeutics, Inc.$183M2.67%3.15%-5.3%Q3 2024
ALMSAlumis Inc.$179M2.60%Not reported-6.3%Q1 2026
IONSIonis Pharmaceuticals Inc$174M2.54%1.33%+12.8%Q4 2022
CMPSCOMPASS Pathways plc$172M2.50%8.96%Not reportedQ2 2023
VERAVera Therapeutics, Inc.$172M2.50%5.57%-2.6%Q4 2025
AXSMAxsome Therapeutics, Inc.$171M2.49%1.34%-36.4%Q2 2023
GMABGenmab A/S$155M2.26%Not reported+54.2%Q4 2024
MLTXMoonLake Immunotherapeutics$136M1.98%9.51%+9.2%Q2 2023
COAGHemab Therapeutics Holdings, Inc.$132M1.93%7.71%NewQ2 2026
TNGXTango Therapeutics, Inc.$131M1.91%2.49%+52.7%Q3 2025
DFTXDefinium Therapeutics, Inc.$129M1.88%2.05%-8.3%Q1 2026
GRALGRAIL, Inc.$125M1.82%4.11%+6.5%Q4 2025
BCAXBicara Therapeutics Inc.$122M1.77%6.22%+0.9%Q3 2024
MAZEMaze Therapeutics, Inc.$111M1.62%6.72%+7.3%Q1 2025
CLDXCelldex Therapeutics, Inc.$109M1.59%3.74%+128.9%Q4 2024
LBRXLB Pharmaceuticals Inc$109M1.58%11.69%Not reportedQ3 2025
MBXMBX Biosciences, Inc.$95.6M1.39%3.61%-37.2%Q3 2024
GHRSGH Research PLC$89.6M1.30%5.37%Not reportedQ4 2021
COGTCogent Biosciences, Inc.$77.4M1.13%1.17%+100.0%Q1 2024
ATAIAtaiBeckley Inc.$76M1.11%3.90%+20.2%Q1 2026
UTHRUNITED THERAPEUTICS Corp$67M0.97%0.29%NewQ2 2026
AVTXAvalo Therapeutics, Inc.$66.7M0.97%6.82%Not reportedQ3 2024
VRDNViridian Therapeutics, Inc.\DE$66M0.96%3.17%+157.7%Q4 2021
CYTKCytokinetics Inc$59.6M0.87%0.56%-49.1%Q4 2023
ALTAltimmune, Inc.$58.5M0.85%9.90%NewQ2 2026
PSNLPersonalis, Inc.$53.6M0.78%3.76%+33.3%Q1 2026
ACRSAclaris Therapeutics, Inc.$49.4M0.72%6.68%Not reportedQ1 2023
CRMDCorMedix Inc.$49.3M0.72%8.08%Not reportedQ3 2025
WGSGeneDx Holdings Corp.$48.1M0.70%2.35%NewQ2 2026
HROWHarrow, Inc.$41.2M0.60%2.59%NewQ2 2026
CRVSCorvus Pharmaceuticals, Inc.$37.2M0.54%2.96%0.0%Q1 2026
SLDBSolid Biosciences Inc.$35.6M0.52%3.39%Not reportedQ1 2026
BEAMBeam Therapeutics Inc.$34.3M0.50%0.97%+21.8%Q4 2021
DYNDyne Therapeutics, Inc.$33.3M0.48%0.91%-25.0%Q4 2021
IMMXImmix Biopharma, Inc.$28.6M0.42%3.88%NewQ2 2026
XFORX4 Pharmaceuticals, Inc$27.5M0.40%6.12%-7.3%Q3 2025
STTKShattuck Labs, Inc.$25.7M0.37%3.68%NewQ2 2026
MNKDMannkind Corp$25.6M0.37%1.94%NewQ2 2026
Q1 2026Reported May 15, 202662 positions
GHGuardant Health, Inc.$308M5.04%2.54%+19.2%Q2 2023
IMVTImmunovant, Inc.$286M4.68%5.65%Not reportedQ4 2021
TARSTarsus Pharmaceuticals, Inc.$253M4.12%8.37%+19.8%Q1 2025
PCVXVaxcyte, Inc.$250M4.08%2.98%+7.5%Q1 2025
GPCRStructure Therapeutics Inc.$206M3.37%2.01%+4.1%Q1 2023
AXSMAxsome Therapeutics, Inc.$186M3.04%2.14%-4.4%Q2 2023
APLSApellis Pharmaceuticals, Inc.$182M2.98%3.54%-41.5%Q1 2024
OCULOcular Therapeutix, Inc$167M2.72%8.99%+143.9%Q4 2023
VERAVera Therapeutics, Inc.$165M2.70%6.42%+45.6%Q4 2025
ALMSAlumis Inc.$149M2.44%Not reportedNewQ1 2026
IONSIonis Pharmaceuticals Inc$146M2.39%1.18%+14.7%Q4 2022
NUVLNuvalent, Inc.$141M2.30%43.98%Not reportedQ4 2023
ALKSAlkermes plc.$127M2.07%2.16%+79.5%Q1 2023
CNTACentessa Pharmaceuticals PLC$125M2.05%2.04%+57.9%Q4 2021
MLTXMoonLake Immunotherapeutics$119M1.95%12.16%+39.0%Q2 2023
MAZEMaze Therapeutics, Inc.$104M1.70%6.99%-18.1%Q1 2025
ORKAOruka Therapeutics, Inc.$99.8M1.63%4.05%-5.9%Q3 2024
NRIXNurix Therapeutics, Inc.$98.4M1.61%6.14%-9.8%Q2 2022
GMABGenmab A/S$98.3M1.61%Not reportedNot reportedQ4 2024
CYTKCytokinetics Inc$90.6M1.48%1.12%-58.8%Q4 2023
GRALGRAIL, Inc.$89M1.45%4.19%+68.4%Q4 2025
LBRXLB Pharmaceuticals Inc$82.7M1.35%11.69%Not reportedQ3 2025
MBXMBX Biosciences, Inc.$82.3M1.34%5.80%-15.2%Q3 2024
BCAXBicara Therapeutics Inc.$80.8M1.32%6.20%+55.4%Q3 2024
CMPSCOMPASS Pathways plc$67.3M1.10%9.01%+65.8%Q2 2023
BMRNBiomarin Pharmaceutical Inc$65M1.06%0.60%-50.0%Q2 2022
BBIOBridgeBio Pharma, Inc.$62.5M1.02%0.43%+3.9%Q4 2024
IMCRImmunocore Holdings plc$58.2M0.95%3.80%-3.6%Q4 2024
TNGXTango Therapeutics, Inc.$57.5M0.94%1.91%+12.0%Q3 2025
DFTXDefinium Therapeutics, Inc.$56.7M0.93%2.88%NewQ1 2026
TERNTerns Pharmaceuticals, Inc.$56.6M0.92%0.93%+39.6%Q2 2023
GERNGeron Corp$47.3M0.77%4.95%-2.4%Q4 2022
ANIPAni Pharmaceuticals Inc$46.1M0.75%2.67%+25.6%Q2 2023
CRMDCorMedix Inc.$42.6M0.70%8.00%+19.0%Q3 2025
ATAIAtaiBeckley Inc.$42.5M0.69%3.28%NewQ1 2026
CLDXCelldex Therapeutics, Inc.$40.7M0.67%1.93%-32.5%Q4 2024
COGTCogent Biosciences, Inc.$38.5M0.63%0.59%+120.7%Q1 2024
CRVSCorvus Pharmaceuticals, Inc.$36.5M0.60%2.96%NewQ1 2026
DYNDyne Therapeutics, Inc.$36.3M0.59%1.21%-24.5%Q4 2021
SLNOSoleno Therapeutics Inc$36.1M0.59%2.09%+7.9%Q4 2025
ACRSAclaris Therapeutics, Inc.$35M0.57%6.69%Not reportedQ1 2023
MANEVeradermics, Inc$31.6M0.52%1.34%NewQ1 2026
VSTMVerastem, Inc.$30.4M0.50%6.54%Not reportedQ4 2025
ENGNenGene Therapeutics Inc.$29.8M0.49%6.53%Not reportedQ1 2024
VRDNViridian Therapeutics, Inc.\DE$27.3M0.45%1.36%-44.8%Q4 2021
XFORX4 Pharmaceuticals, Inc$26.2M0.43%6.72%+26.5%Q3 2025
SLDBSolid Biosciences Inc.$25.7M0.42%3.62%NewQ1 2026
ENTAEnanta Pharmaceuticals Inc$24.7M0.40%6.73%Not reportedQ1 2022
APGEApogee Therapeutics, Inc.$24M0.39%0.38%Not reportedQ3 2023
KURAKura Oncology, Inc.$21.5M0.35%2.98%Not reportedQ4 2021
Q4 2025Reported Feb 13, 202652 positions
IMVTImmunovant, Inc.$293M5.22%5.67%+18.5%Q4 2021
GHGuardant Health, Inc.$286M5.10%2.14%-32.6%Q2 2023
GPCRStructure Therapeutics Inc.$286M5.10%1.93%-2.5%Q1 2023
TARSTarsus Pharmaceuticals, Inc.$246M4.39%7.06%+0.1%Q1 2025
DVAXDynavax Technologies Corp$242M4.31%13.39%Not reportedQ4 2022
CYTKCytokinetics Inc$212M3.78%2.71%-22.4%Q4 2023
AXSMAxsome Therapeutics, Inc.$210M3.74%2.26%+27.8%Q2 2023
APLSApellis Pharmaceuticals, Inc.$195M3.47%6.12%-3.1%Q1 2024
PCVXVaxcyte, Inc.$185M3.29%3.05%+33.3%Q1 2025
MAZEMaze Therapeutics, Inc.$176M3.14%8.61%+7.5%Q1 2025
VERAVera Therapeutics, Inc.$143M2.55%4.41%NewQ4 2025
BMRNBiomarin Pharmaceutical Inc$137M2.44%1.20%+9153.3%Q2 2022
IONSIonis Pharmaceuticals Inc$134M2.40%1.04%-55.4%Q4 2022
NRIXNurix Therapeutics, Inc.$133M2.38%6.91%+16.2%Q2 2022
MBXMBX Biosciences, Inc.$102M1.83%7.23%+3.2%Q3 2024
OCULOcular Therapeutix, Inc$98M1.75%3.74%-32.4%Q4 2023
GRALGRAIL, Inc.$87.5M1.56%2.54%NewQ4 2025
VRDNViridian Therapeutics, Inc.\DE$78.6M1.40%2.48%-53.1%Q4 2021
LBRXLB Pharmaceuticals Inc$74.6M1.33%13.25%Not reportedQ3 2025
IMCRImmunocore Holdings plc$69.6M1.24%3.95%+11.3%Q4 2024
ORKAOruka Therapeutics, Inc.$65.5M1.17%4.44%-18.6%Q3 2024
BBIOBridgeBio Pharma, Inc.$62M1.10%0.42%-32.5%Q4 2024
CRMDCorMedix Inc.$61.3M1.09%6.65%+954.8%Q3 2025
MLTXMoonLake Immunotherapeutics$60.8M1.08%8.75%Not reportedQ2 2023
ALKSAlkermes plc.$56M1.00%1.21%Not reportedQ1 2023
DYNDyne Therapeutics, Inc.$51.8M0.92%1.61%+32.5%Q4 2021
CLDXCelldex Therapeutics, Inc.$51.6M0.92%2.86%-5.0%Q4 2024
CMPSCOMPASS Pathways plc$50.6M0.90%7.63%-6.7%Q2 2023
CNTACentessa Pharmaceuticals PLC$50M0.89%1.34%Not reportedQ4 2021
SLNOSoleno Therapeutics Inc$46.3M0.83%1.91%NewQ4 2025
VSTMVerastem, Inc.$44.3M0.79%7.38%NewQ4 2025
BCAXBicara Therapeutics Inc.$44M0.78%4.62%+7.7%Q3 2024
GERNGeron Corp$42.9M0.77%5.08%-20.9%Q4 2022
ENGNenGene Therapeutics Inc.$39.5M0.70%6.54%+95.5%Q1 2024
ANIPAni Pharmaceuticals Inc$37.7M0.67%2.12%+6.2%Q2 2023
TERNTerns Pharmaceuticals, Inc.$31.1M0.55%0.68%-89.7%Q2 2023
ENTAEnanta Pharmaceuticals Inc$30.9M0.55%6.74%Not reportedQ1 2022
MNMDDefinium Therapeutics, Inc.$22.4M0.40%Not reported+11.8%Q1 2024
TNGXTango Therapeutics, Inc.$21.7M0.39%1.81%+68.8%Q3 2025
XFORX4 Pharmaceuticals, Inc$20.1M0.36%5.52%+346.7%Q3 2025
XENEXenon Pharmaceuticals Inc.$16.4M0.29%0.46%-69.5%Q4 2024
COGTCogent Biosciences, Inc.$16.1M0.29%0.28%Not reportedQ1 2024
HELPCybin Inc.$15.2M0.27%8.58%+85.4%Q3 2024
CNTXContext Therapeutics Inc.$10.9M0.19%8.08%Not reportedQ2 2024
MNPRMonopar Therapeutics$6.23M0.11%1.43%NewQ4 2025
CBIOCrescent Biopharma, Inc.$5.38M0.10%1.65%Not reportedQ2 2025
ALGSAligos Therapeutics, Inc.$4.14M0.07%7.19%Not reportedQ4 2023
BLLNBillionToOne, Inc.$4.09M0.07%0.45%NewQ4 2025
RAPTRAPT Therapeutics, Inc.$3.74M0.07%0.40%-85.3%Q4 2022
IVAInventiva S.A.$2.28M0.04%0.25%NewQ4 2025
Q3 2025Reported Nov 14, 202556 positions
GHGuardant Health, Inc.$260M7.24%3.32%-2.3%Q2 2023
IONSIonis Pharmaceuticals Inc$249M6.95%2.36%-22.2%Q4 2022
CYTKCytokinetics Inc$236M6.60%3.59%+17.8%Q4 2023
AKROAkero Therapeutics, Inc.$190M5.30%4.99%+31.5%Q3 2022
APLSApellis Pharmaceuticals, Inc.$181M5.05%6.32%+14.3%Q1 2024
TARSTarsus Pharmaceuticals, Inc.$178M4.98%7.07%+71.4%Q1 2025
IMVTImmunovant, Inc.$157M4.38%5.57%+2.4%Q4 2021
DVAXDynavax Technologies Corp$156M4.36%13.40%-11.6%Q4 2022
OCULOcular Therapeutix, Inc$139M3.89%6.82%-16.5%Q4 2023
ETNB89bio, Inc.$138M3.84%6.31%-1.5%Q3 2022
GPCRStructure Therapeutics Inc.$118M3.29%2.32%-17.9%Q1 2023
VRDNViridian Therapeutics, Inc.\DE$116M3.24%6.54%Not reportedQ4 2021
PTGXProtagonist Therapeutics, Inc$114M3.18%2.75%-47.1%Q4 2021
AXSMAxsome Therapeutics, Inc.$109M3.05%1.79%+12.3%Q2 2023
PCVXVaxcyte, Inc.$108M3.02%2.31%+39.5%Q1 2025
MAZEMaze Therapeutics, Inc.$102M2.86%8.21%Not reportedQ1 2025
IMCRImmunocore Holdings plc$65.4M1.82%3.57%Not reportedQ4 2024
BBIOBridgeBio Pharma, Inc.$62.3M1.74%0.62%+33.3%Q4 2024
GERNGeron Corp$56.3M1.57%6.44%-4.4%Q4 2022
TERNTerns Pharmaceuticals, Inc.$56.3M1.57%8.56%Not reportedQ2 2023
NRIXNurix Therapeutics, Inc.$56M1.56%7.88%-0.1%Q2 2022
MBXMBX Biosciences, Inc.$55.1M1.54%7.04%+43.9%Q3 2024
EXKEndeavour Silver Corp$54.7M1.53%0.38%NewQ3 2025
LBRXLB Pharmaceuticals Inc$52.9M1.48%13.25%NewQ3 2025
CLDXCelldex Therapeutics, Inc.$51.7M1.44%3.01%Not reportedQ4 2024
ORKAOruka Therapeutics, Inc.$51.1M1.42%5.49%+38.4%Q3 2024
XENEXenon Pharmaceuticals Inc.$48.2M1.34%1.56%-11.1%Q4 2024
CMPSCOMPASS Pathways plc$45M1.26%8.19%-11.0%Q2 2023
ANIPAni Pharmaceuticals Inc$41.2M1.15%2.13%-35.7%Q2 2023
BCAXBicara Therapeutics Inc.$38.3M1.07%4.44%Not reportedQ3 2024
OLMAOlema Pharmaceuticals, Inc.$34M0.95%5.05%+0.8%Q3 2023
CDTXCidara Therapeutics, Inc.$28.7M0.80%1.02%+20.0%Q2 2025
QUREuniQure N.V.$28.2M0.79%0.78%Not reportedQ1 2023
DYNDyne Therapeutics, Inc.$25.3M0.71%1.40%Not reportedQ4 2021
JBIOJade Biosciences, Inc.$19.7M0.55%6.99%-9.1%Q2 2025
RAPTRAPT Therapeutics, Inc.$19.4M0.54%4.54%Not reportedQ4 2022
GHRSGH Research PLC$17.9M0.50%2.40%-37.5%Q4 2021
MNMDDefinium Therapeutics, Inc.$17.7M0.49%Not reported-40.0%Q1 2024
ENGNenGene Therapeutics Inc.$15.3M0.43%4.37%-50.9%Q1 2024
GMABGenmab A/S$14.8M0.41%Not reportedNot reportedQ4 2024
TNGXTango Therapeutics, Inc.$12.2M0.34%1.30%NewQ3 2025
CNTXContext Therapeutics Inc.$7.19M0.20%8.08%Not reportedQ2 2024
IMAImageneBio, Inc.$7.16M0.20%21.85%NewQ3 2025
XNCRXencor Inc$6.44M0.18%0.77%Not reportedQ3 2024
HELPCybin Inc.$5.89M0.16%4.63%-34.6%Q3 2024
CRMDCorMedix Inc.$5.82M0.16%0.64%NewQ3 2025
PEPGPepGen Inc.$5.54M0.15%3.66%NewQ3 2025
CBIOCrescent Biopharma, Inc.$5.39M0.15%3.27%Not reportedQ2 2025
ALGSAligos Therapeutics, Inc.$4.35M0.12%7.22%Not reportedQ4 2023
AUTLAutolus Therapeutics plc$4.19M0.12%0.97%-84.8%Q1 2022
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.